NRx Pharmaceuticals NRXP Stock
NRx Pharmaceuticals Price Chart
NRx Pharmaceuticals NRXP Financial and Trading Overview
| NRx Pharmaceuticals stock price | 4.14 USD |
| Previous Close | 4.42 USD |
| Open | 4.49 USD |
| Bid | 3.48 USD x 200 |
| Ask | 5.72 USD x 200 |
| Day's Range | 4.43 - 4.86 USD |
| 52 Week Range | 1.62 - 4.86 USD |
| Volume | 1.74M USD |
| Avg. Volume | 1.08M USD |
| Market Cap | 167.38M USD |
| Beta (5Y Monthly) | 2.017 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.04 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42 USD |
NRXP Valuation Measures
| Enterprise Value | 161.45M USD |
| Trailing P/E | N/A |
| Forward P/E | 9.24 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 72.99518 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 70.409 |
| Enterprise Value/EBITDA | -9.465 |
Trading Information
NRx Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 2.017 |
| 52-Week Change | 64.92% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 4.86 USD |
| 52 Week Low | 1.62 USD |
| 50-Day Moving Average | 2.8 USD |
| 200-Day Moving Average | 2.55 USD |
NRXP Share Statistics
| Avg. Volume (3 month) | 1.08M USD |
| Avg. Daily Volume (10-Days) | 1.72M USD |
| Shares Outstanding | 36.23M |
| Float | 30.45M |
| Short Ratio | 3.74 |
| % Held by Insiders | 7.58% |
| % Held by Institutions | 17.45% |
| Shares Short | 4.67M |
| Short % of Float | 13.56% |
| Short % of Shares Outstanding | 12.88% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -444.56% |
| Gross Margin | 50.45% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -110.22% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 2.29M USD |
| Revenue Per Share (ttm) | 0.09 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 1.16M USD |
| EBITDA | -17057000 USD |
| Net Income Avi to Common (ttm) | -24540000 USD |
| Diluted EPS (ttm) | -1.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.71M USD |
| Total Cash Per Share (mrq) | 0.19 USD |
| Total Debt (mrq) | 934K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.292 |
| Book Value Per Share (mrq) | -0.413 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14927000 USD |
| Levered Free Cash Flow (ttm) | -8542125 USD |
Profile of NRx Pharmaceuticals
| Country | United States |
| State | DE |
| City | Wilmington |
| Address | 1201 N. Market Street |
| ZIP | 19801 |
| Phone | 484 254 6134 |
| Website | https://www.nrxpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29 |
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Q&A For NRx Pharmaceuticals Stock
What is a current NRXP stock price?
NRx Pharmaceuticals NRXP stock price today per share is 4.14 USD.
How to purchase NRx Pharmaceuticals stock?
You can buy NRXP shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NRx Pharmaceuticals?
The stock symbol or ticker of NRx Pharmaceuticals is NRXP.
Which industry does the NRx Pharmaceuticals company belong to?
The NRx Pharmaceuticals industry is Biotechnology.
How many shares does NRx Pharmaceuticals have in circulation?
The max supply of NRx Pharmaceuticals shares is 36.23M.
What is NRx Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
NRx Pharmaceuticals PE Ratio is now.
What was NRx Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
NRx Pharmaceuticals EPS is -1.04 USD over the trailing 12 months.
Which sector does the NRx Pharmaceuticals company belong to?
The NRx Pharmaceuticals sector is Healthcare.
NRx Pharmaceuticals NRXP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26674.14 USD — |
-0.67
|
2.69B USD — | 26554.24 USD — | 26702.78 USD — | — - | 2.69B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2328.43 USD — |
+1.41
|
— — | 2280.63 USD — | 2328.72 USD — | — - | — — |
| US Tech Biotechnology NBI | 5966.36 USD — |
+2.74
|
— — | 5868.75 USD — | 5967.75 USD — | — - | — — |
| US Tech Health Care IXHC | 1165.39 USD — |
+2.81
|
— — | 1146.48 USD — | 1165.81 USD — | — - | — — |
- {{ link.label }} {{link}}